The global obesity epidemic, affecting over one billion people worldwide, is largely driven by eating behaviors. Appetite, influenced by both intrinsic and environmental factors, plays a crucial role in weight management. A recent study how exercise affects appetite perception in obese males, shedding light on the physiological mechanisms behind hunger suppression post-exercise.
While exercise is well-known for its benefits in weight management, its direct impact on appetite control has remained a subject of debate. Appetite is regulated by a complex network of gastrointestinal and neurohormonal signals, including hormones like ghrelin, leptin, interleukin 6 (IL-6), and neuropeptide Y (NPY). These hormones influence hunger levels, satiety, and energy balance.
The study published in Physiological Reports examines investigated how moderate continuous aerobic exercise (MICE) alters these hormone levels in obese men, ultimately affecting their hunger perception. The findings reveal that certain myokines and cytokines shift dynamically post-exercise, potentially reducing appetite and offering a promising strategy for weight management.
The study found that after exercise, there was a significant increase in IL-6 and irisin levels in the exercise group compared to those who remained sedentary. These elevated concentrations persisted for an hour after working out. IL-6 has been associated with regulating metabolism and enhancing fat oxidation, while irisin plays a role in converting white fat into more metabolically active brown fat.
Conversely, the study reported a decrease in neuropeptide Y (NPY) levels, a key neurotransmitter responsible for stimulating appetite. The decline in NPY levels post-exercise suggests a temporary suppression of hunger, supporting the idea that exercise can curb cravings. However, the study did not observe significant changes in IL-7 or leptin levels, two other hormones involved in appetite regulation.
Ghrelin, often called the “hunger hormone,” stimulates appetite by increasing activity in specific areas of the brain. Individuals with higher ghrelin levels generally find it harder to lose weight because their bodies signal hunger more frequently.
Research suggests that dieting can lead to an increase in ghrelin levels, making weight loss challenging. Certain medical conditions, such as Hashimoto’s thyroiditis, Prader-Willi syndrome, anorexia nervosa, and bulimia nervosa, are also linked to elevated ghrelin levels, complicating appetite regulation further.
While exercise has clear benefits, the findings should be interpreted with caution. He pointed out that the study had a small sample size, making it difficult to draw definitive conclusions.
Moreover, he highlighted the challenges faced by obese individuals in maintaining an intensive exercise routine. While exercise-induced appetite suppression is promising, consistently engaging in high-intensity workouts may be unrealistic for those who struggle with mobility or fitness levels. More extensive studies are needed to determine the optimal exercise duration and intensity for effective appetite suppression.
Besides exercise, there are several strategies individuals can use to naturally suppress their appetite and improve satiety:
Increase Protein Intake: Protein-rich foods, such as lean meats, legumes, and dairy, promote feelings of fullness and reduce hunger.
Stay Hydrated: Drinking water before meals can help control portion sizes and prevent overeating.
Opt for Fiber-Rich Foods: Whole grains, vegetables, and fruits high in fiber take longer to digest, keeping you full for longer.
Reduce Simple Carbohydrates and Sugars: Simple carbs and sugars cause rapid spikes and crashes in blood sugar levels, leading to increased hunger.
Prioritize Sleep: Poor sleep disrupts hunger-regulating hormones, making it harder to control cravings.
Manage Stress: Chronic stress increases cortisol levels, which can lead to overeating and weight gain.
The study’s findings indicate that moderate exercise can temporarily suppress appetite by altering key hormones. While more research is needed to refine the details—such as optimal workout duration and intensity—this insight adds to the growing body of evidence supporting exercise as a tool for appetite regulation and weight management.
For individuals looking to curb cravings and maintain a healthy weight, incorporating a well-balanced diet alongside regular exercise remains the most sustainable approach. Future studies focusing on larger populations and long-term effects could provide deeper insights into how exercise can be optimized for appetite control, making it an effective strategy in combating obesity.
Exercise alone is not a magic solution for weight loss, but its impact on appetite hormones presents a promising avenue for managing hunger and energy balance. As research continues to evolve, it becomes increasingly clear that integrating physical activity with mindful eating habits can play a vital role in achieving and maintaining a healthy lifestyle.
Credit: AI-generated image
What happens when people stop taking GLP-1 weight-loss injections like Ozempic, Wegovy or Mounjaro? Do they regain weight, switch to another medication or consider bariatric surgery?
A new study published in The Lancet's eClinicalMedicine examined that what people do after their initial GLP-1 treatment can make a significant difference in their long-term weight outcomes.
Researchers at Cleveland Clinic examined health records from 20,486 patients who had taken semaglutide or tirzepatide injections for at least three months.
They compared five weight loss maintenance over a two-year period: continuing the original weight loss medication, switching between the two drugs, moving to another obesity medication, undergoing bariatric surgery or stopping treatment altogether without pursuing another option.
After two years, the average weight reductions were:
These results indicate that discontinuing GLP-1 treatment does not mean all the lost weight will come back. But patients who stopped treatment without another medical or surgical intervention experienced the lowest success in keeping the weight off.
The study also found that the outcomes of switching depended on which medication patients were taking initially. Those who moved from semaglutide to tirzepatide lost more weight than those who continued semaglutide. However, among people initially taking tirzepatide, remaining on the medication led to greater weight loss than switching to semaglutide.
Also read: Stopping Ozempic or Wegovy May Double Your Risk Of Heart Attack, Death
Not just weight loss, the findings also covered metabolic outcomes as patients with existing health conditions also showed significant differences.
Among participants with type 2 diabetes, bariatric surgery proved to drive major improvement in HbA1c. This was followed by switching between semaglutide and tirzepatide, continuing the original medication and moving to another obesity drug.
Patients with hypertension who continued treatment also experienced greater reductions in blood pressure than those who stopped.
Those who discontinued treatment without another intervention showed the smallest improvements in blood glucose control and blood pressure.
GLP-1 medications have become increasingly popular for managing diabetes and combating obesity, but long-term treatment can be difficult for some patients to maintain.
Cost, insurance and side effects are among the reasons why people may discontinue these medicines. Gastrointestinal symptoms like nausea, vomiting, diarrhoea and constipation can also affect adherence to treatment.
People who cannot continue their original medication, and are considering switching to another treatment or considering bariatric surgery should discuss their options with their healthcare providers.
Lead author Hamlet Gasoyan, a researcher at Cleveland Clinic's Center for Value-Based Care Research, said, “The encouraging news is that, for patients who need to stop their injectable GLP-1 medication, it does not mean that their obesity treatment journey has to end.”
Co-author Ali Aminian, director of Cleveland Clinic's Bariatric and Metabolic Institute, added, “When a patient stops a GLP-1 medication, the most important question is what comes next.”
He noted that patients who stopped all treatment had the least weight loss while those who moved on to another therapy, particularly bariatric surgery, did significantly better.
Credit: iStock
For years, body mass index (BMI) has been a key health marker to track obesity. But a recent study suggests that not everyone classified as obese based on their BMI may have obesity-related health problems. Researchers say just considering BMI alone may lead to incorrect diagnosis in some people while overlooking others with excess body fat and related health risks.
The international study, involving more than 844,000 adults across China, the UK, the US and Spain, supports a different approach that considers body fat distribution, waist measurement and the impact of excess fat on organ function.
Researchers propose distinguishing between two categories: pre-clinical obesity, in which excess body fat increases health risks but has not impaired organ function, and clinical obesity, in which excess fat is already affecting the body's ability to function.
BMI is calculated by dividing a person's weight in kilograms by their height in metres squared. It is used to classify people as underweight, normal weight, overweight or obese.
However, BMI does not directly measure body fat or show where fat is distributed. It also cannot distinguish between fat and muscle mass. Consequently, two people with the same BMI may have very different body compositions and health risks.
The researchers found that adding waist circumference and waist-to-height ratio to BMI helped identify people whose excess body fat might otherwise be missed.
The analysis suggested that BMI alone missed obesity level body fat in up to 8.6% of participants, while incorrectly classifying up to 3.1% as having obesity in the study groups.
Professor Francesco Rubino, senior author of the study and Chair of Metabolic and Bariatric Surgery at King's College London, said, “Body mass index alone cannot tell us whether someone is already ill or at risk of illness, or what care they need, leaving people vulnerable to both undertreatment and overtreatment.”
Also read: Loud Snoring Is Not Always Harmless: Sleep Apnoea can Become a Stroke-Risk Concern
The researchers used a framework proposed by the Lancet Diabetes and Endocrinology Commission in 2025. It separates obesity into two categories based on whether excess body fat has affected a person's health.
The study estimated that only around 23% to 31% of people classified as having obesity across the four study populations had clinical obesity. This represented approximately 5.6% to 10.9% of the overall adult populations studied.
The researchers followed participants over time to examine how often pre-clinical obesity progressed to clinical obesity.
They found that approximately 77% to 91% of people classified as having pre-clinical obesity did not progress to clinical obesity over 10 years. However, progression rates differed across the study populations.
Clinical obesity was linked with a higher risk of death while pre-clinical obesity had a more modest increase in risk.
Professor Rubino said, “Preclinical obesity should therefore be neither treated automatically as active disease nor dismissed as harmless. Some people may need preventive treatment, but its intensity should match their individual risk.”
The findings do not mean that people with pre-clinical obesity should ignore excess body fat. Rather, they highlight the importance of assessing individual health risks instead of making treatment decisions based on BMI alone.
People with excess body fat may still benefit from lifestyle hanges, treatment and preventive care even if they have not developed organ dysfunction.
Credit: AI
Smartwatches and fitness trackers are widely used for counting daily steps and tracking workouts by millions. But the World Health Organization (WHO) is now seeking to task these wearables with bigger responsibilities. The global health body has issued proposals for wearable devices that could help countries measure physical activity and sedentary behaviour across populations.
In a notice published on November 8, WHO invited researchers, health authorities, technology developers and other stakeholders to review a draft Target Product Profile (TPP) for wearable devices worn on wrists. The aim is to ascertain what these devices should be capable of measuring before they are incorporated into national and subnational public health monitoring systems.
The proposal will remain open until December 6, 2026. WHO will use the feedback to revise and finalise the document and inform future implementation guidance.
Physical inactivity is a major risk factor for non-communicable diseases, including cardiovascular disease, type 2 diabetes and certain cancers. Sedentary behaviour, which involves spending prolonged periods sitting is also the cause of various adverse health outcomes.
Countries currently rely heavily on surveys to understand how physically active people are. However, these often depend on people reporting their own activity, which can lead to inaccurate data.
Wearable devices could provide a more objective way to collect information over a certain period of time. Instead of relying entirely on questionnaires, health authorities could use data from these devices to understand how much people move, how long they remain sedentary and how activity patterns vary across different population groups.
WHO says wearable technology could complement existing surveillance methods as countries work towards improving global physical activity targets.
Also read: Weight Loss Without Extreme Diets: What Sustainable Medical Weight Management Looks Like
The draft TPP outlines minimum specifications for smartwatches intended for population-level monitoring. It considers what makes a device suitable for collecting data across different populations.
The proposed framework covers:
WHO is interested in feedback on whether the specifications proposed are practical and relevant to countries with limited resources.
Although such wearables are widely available, their measurements are not interchangeable. Different manufacturers use different sensors, algorithms and methods to calculate steps, activity levels and sedentary time. As a result, two devices worn by the same person may produce different estimates.
A systematic review published in npj Digital Medicine in January 2026 examined 82 studies evaluating Apple Watch measurements across 14 health metrics. It found that measurement accuracy varied depending on the metric and testing conditions. While heart-rate measurements showed good overall agreement, step counts had moderate accuracy and energy expenditure data was inconsistent too.
This illustrates the need for standardisation. If countries use different devices and measurement methods, comparing physical activity data across populations becomes needlessly challenging.
WHO's proposed framework is intended to address these differences by identifying the device characteristics and protocols needed for consistent data collection.
Cost, access, privacy and digital literacy remain important challenges when it comes to implementing WHO's proposal. People without smartphones, reliable internet access or the ability to buy wearable devices could be underrepresented.
There are also questions about how personal movement data would be stored, shared and protected. Governments would need clear safeguards to ensure that participation is voluntary, data is handled responsibly and findings represent the wider population.
© $2026 Times Horizon Private Limited